ATE546735T1 - Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afp - Google Patents
Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afpInfo
- Publication number
- ATE546735T1 ATE546735T1 AT09738132T AT09738132T ATE546735T1 AT E546735 T1 ATE546735 T1 AT E546735T1 AT 09738132 T AT09738132 T AT 09738132T AT 09738132 T AT09738132 T AT 09738132T AT E546735 T1 ATE546735 T1 AT E546735T1
- Authority
- AT
- Austria
- Prior art keywords
- expression level
- pro
- epil
- biomarker
- combination
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4841208P | 2008-04-28 | 2008-04-28 | |
| PCT/EP2009/055100 WO2009133088A1 (en) | 2008-04-28 | 2009-04-28 | PRO-EPIL EXPRESSION LEVEL IN A BIOLOGICAL SAMPLE AS TESTICULAR CANCER BIOMARKER, PARTICULARLY IN COMBINATION WITH THE HCGβ AND AFP BIOMARKERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE546735T1 true ATE546735T1 (de) | 2012-03-15 |
Family
ID=40801785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09738132T ATE546735T1 (de) | 2008-04-28 | 2009-04-28 | Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afp |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110105365A1 (de) |
| EP (1) | EP2281195B1 (de) |
| AT (1) | ATE546735T1 (de) |
| ES (1) | ES2380552T3 (de) |
| WO (1) | WO2009133088A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2653870A1 (de) | 2012-04-17 | 2013-10-23 | Universite Paris Descartes | Verfahren zur Auswahl von Serumbiomarkern eipigenetischer Veränderungen, insbesondere der globalen Hypomethylierung und ihre Verwendungen |
| CN115927333B (zh) * | 2022-10-27 | 2025-05-06 | 中国科学技术大学 | piR-36249基因类似物及其在预防和治疗癌症中的用途 |
| CN119410774B (zh) * | 2024-11-01 | 2025-06-03 | 上海爱谱蒂康生物科技有限公司 | 一种生物标志物组合及其在预测睾丸癌风险中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2721033B1 (fr) * | 1994-06-13 | 1996-08-30 | Roussy Inst Gustave | Nouvelle protéine dénommée placentine, procédé de préparation de cette protéine et composition pharmaceutique la contenant, ADN codant pour ladite protéine. |
| FR2767326B1 (fr) * | 1997-08-14 | 2001-06-22 | Roussy Inst Gustave | Identification et localisation de polypeptides epil exprimes codes par le gene insl4 et leurs applications |
-
2009
- 2009-04-28 AT AT09738132T patent/ATE546735T1/de active
- 2009-04-28 ES ES09738132T patent/ES2380552T3/es active Active
- 2009-04-28 WO PCT/EP2009/055100 patent/WO2009133088A1/en not_active Ceased
- 2009-04-28 US US12/989,999 patent/US20110105365A1/en not_active Abandoned
- 2009-04-28 EP EP09738132A patent/EP2281195B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP2281195A1 (de) | 2011-02-09 |
| WO2009133088A1 (en) | 2009-11-05 |
| EP2281195B1 (de) | 2012-02-22 |
| US20110105365A1 (en) | 2011-05-05 |
| ES2380552T3 (es) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX368394B (es) | Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato. | |
| GB201009641D0 (en) | Methods of monitoring conditions by sequence analysis | |
| NZ624816A (en) | Ratio based biomarkers and methods of use thereof | |
| ATE554389T1 (de) | Apex als marker für lungenkrebs | |
| EP4083233A3 (de) | Verfahren zur verwendung von genexpression zur bestimmung der prognose von prostatakrebs | |
| WO2011072177A3 (en) | Biomarker assay for diagnosis and classification of cardiovascular disease | |
| AR084723A1 (es) | microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR | |
| MX355020B (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
| MX2011011571A (es) | Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia. | |
| Leung et al. | Ovarian cancer biomarkers: current state and future implications from high-throughput technologies | |
| WO2009019367A3 (fr) | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal | |
| BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico | |
| MY195697A (en) | Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof | |
| ATE430936T1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
| PE20120592A1 (es) | Metodo con biomarcadores para el seguimiento de un tratamiento | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| WO2008122447A3 (en) | Dna methylation assay for the diagnosis or prognosis of medical conditions | |
| EP1930445A4 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| ES2530574T3 (es) | Biomarcadores asociados a la nefropatía | |
| WO2013119279A3 (en) | Assays and methods for the diagnosis of ovarian cancer | |
| WO2011049322A3 (ko) | 유방암 진단을 위한 유방암 특이적 메틸화 마커 유전자의 메틸화 검출방법 | |
| Becker | Improved methods and standards for telomerase detection: quantitative histopathology using antibody staining | |
| Li et al. | Aggregation-Induced Emission Probe/Graphene Oxide Aptasensor for Label-free and" turn-on" fluorescent detection of cancerous exosomes | |
| Becker | Improved methods and standards for telomerase assay: Quantitative histopathology using antibody staining |